Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

lilly-portugal, produtos farmacêuticos, lda. - atomoxetina - cápsula - 25 mg - atomoxetina, cloridrato 28.57 mg - atomoxetine - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

lilly-portugal, produtos farmacêuticos, lda. - atomoxetina - cápsula - 80 mg - atomoxetina, cloridrato 91.42 mg - atomoxetine - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

lilly-portugal, produtos farmacêuticos, lda. - atomoxetina - solução oral - 4 mg/ml - atomoxetina, cloridrato 4.6 mg/ml - atomoxetine - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

lilly-portugal, produtos farmacêuticos, lda. - atomoxetina - cápsula - 60 mg - atomoxetina, cloridrato 68.56 mg - atomoxetine - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

eumedica n.v. - pimozida - comprimido - 4 mg - pimozida 4 mg - pimozide - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

eumedica n.v. - pimozida - comprimido - 4 mg - pimozida 4 mg - pimozide - n/a - duração do tratamento: longa duração

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

legrand pharma indÚstria farmacÊutica ltda - imiquimode - imunomodulador

União Europeia - português - EMA (European Medicines Agency)

sandoz gmbh - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; arthritis, juvenile rheumatoid; crohn disease; skin diseases, papulosquamous - imunossupressores - rheumatoid arthritishyrimoz in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hyrimoz pode ser administrado como monoterapia em caso de intolerância ao metotrexato ou quando a continuidade do tratamento com metotrexato é inadequados. adalimumab tem sido mostrado para reduzir a taxa de progressão do dano articular, como medido por raio-x e para melhorar a função física, quando administrado em combinação com metotrexato. juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritishyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). hyrimoz pode ser administrado como monoterapia em caso de intolerância ao metotrexato ou quando a continuidade do tratamento com metotrexato é inadequados. adalimumab não foi estudado em pacientes com idade inferior a 2 anos. - enthesitis-related arthritishyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritis- ankylosing spondylitis (as)hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. - axial spondyloarthritis without radiographic evidence of ashyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs. psoriatic arthritishyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumab tem sido mostrado para reduzir a taxa de progressão das lesões das articulações periféricas, conforme medido pelo raio-x em pacientes com poliarticular simétrica subtipos da doença e melhorar a função física. psoriasishyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy. crohn’s diseasehyrimoz is indicated for treatment of moderately to severely active crohn’s disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehyrimoz is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.  paediatric ulcerative colitishyrimoz is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. ulcerative colitishyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishyrimoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

mundipharma brasil produtos mÉdicos e farmacÊuticos ltda - maleato de timolol - antiglaucomatosos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - naproxeno, esomeprazol magnésico tri-hidratado - agentes antiinflamatÓrios/antireumÁticos em associaÇÃo